Embed Notice

HTML Code

<blockquote style="position: relative; padding-left: 55px;"><section><a href="https://toad.social/users/minorusaba/statuses/113382478748087117">Minoru Saba (minorusaba@toad.social)'s status on Monday, 28-Oct-2024 10:35:29 JST</a><a href="https://toad.social/@minorusaba" title="minorusaba@toad.social"><img src="https://gnusocial.jp/avatar/139443-48-20230930221108.webp" width="48" height="48" alt="Minoru Saba" style="position: absolute; left: 0; top: 0;">Minoru Saba</a><div><a href="https://gnusocial.jp/notice/7607417" rel="in-reply-to">in reply to</a><ul><li></ul></div></section><article><p><a href="https://famichiki.jp/@salyavin">@salyavin</a> Doc recommended COVID shots for the elderly, probably because Kp3 variant is reported to evade immunity acquired from previous injections.<br><a href="https://www.japantimes.co.jp/news/2024/07/24/japan/science-health/covid-19-11th-wave/" rel="nofollow noreferrer">https://www.japantimes.co.jp/news/2024/07/24/japan/science-health/covid-19-11th-wave/</a> </p><p>Doc didn't say anything about the new Japanese vaccines; Takeda's recombinant protein &amp; Meiji Seika's replicon types make up 8.4% &amp; 13.2% respectively of the total 32.2M doses ordered in Japan for 2024/2025, so majority of clinics probably have stocks of Pfizer/Moderna/Daiichi Sankyo mRNA type.<br><a href="https://news.yahoo.co.jp/expert/articles/12d25237c01916e9fef2f0b85b0180ffc91330ba" rel="nofollow noreferrer">https://news.yahoo.co.jp/expert/articles/12d25237c01916e9fef2f0b85b0180ffc91330ba</a></p></article><footer><a rel="bookmark" href="https://gnusocial.jp/conversation/3884891#notice-7607506">In conversation</a><time datetime="2024-10-28T10:35:29+09:00" title="Monday, 28-Oct-2024 10:35:29 JST">about a month ago</time> <span>from <span><a href="https://toad.social/@minorusaba/113382478748087117" rel="external" title="Sent from toad.social via ActivityPub">toad.social</a></span></span><a href="https://toad.social/@minorusaba/113382478748087117">permalink</a><h4>Attachments</h4><ol><li><article><header><div>Domain not in remote thumbnail source whitelist: www.japantimes.co.jp</div><h5><a href="https://www.japantimes.co.jp/news/2024/07/24/japan/science-health/covid-19-11th-wave/">Japan battling 11th COVID wave, data shows, as KP.3 variant evades immunity</a></h5><div> from <span>/author/int-no_author</span></div></header><div>New infections have been increasing for 10 consecutive weeks amid the rise of the highly transmissible new coronavirus variant.</div><footer></footer></article></li><li><article><header><div>Domain not in remote thumbnail source whitelist: newsatcl-pctr.c.yimg.jp</div><h5><a href="https://news.yahoo.co.jp/expert/articles/12d25237c01916e9fef2f0b85b0180ffc91330ba">１０月から始まる新型コロナワクチン定期接種　誰が対象？　費用はいくら？（倉原優） - エキスパート - Yahoo!ニュース</a></h5><div></div></header><div>１０月１日から、新型コロナワクチンの定期接種が始まります。どのようなワクチンが使用され、接種費用はどのくらいかかるのでしょうか。現時点で分かっていることをお伝えします。接種対象者は？今年の秋冬に、自治</div><footer></footer></article></li></ol></footer></blockquote>

Corresponding Notice

Embed this notice
Minoru Saba (minorusaba@toad.social)'s status on Monday, 28-Oct-2024 10:35:29 JSTMinoru Saba
in reply to
- salyavin
@salyavin Doc recommended COVID shots for the elderly, probably because Kp3 variant is reported to evade immunity acquired from previous injections.
https://www.japantimes.co.jp/news/2024/07/24/japan/science-health/covid-19-11th-wave/
Doc didn't say anything about the new Japanese vaccines; Takeda's recombinant protein & Meiji Seika's replicon types make up 8.4% & 13.2% respectively of the total 32.2M doses ordered in Japan for 2024/2025, so majority of clinics probably have stocks of Pfizer/Moderna/Daiichi Sankyo mRNA type.
https://news.yahoo.co.jp/expert/articles/12d25237c01916e9fef2f0b85b0180ffc91330ba
In conversationabout a month ago from toad.socialpermalink
Attachments
1. Domain not in remote thumbnail source whitelist: www.japantimes.co.jp
  Japan battling 11th COVID wave, data shows, as KP.3 variant evades immunity
  from /author/int-no_author
  New infections have been increasing for 10 consecutive weeks amid the rise of the highly transmissible new coronavirus variant.
2. Domain not in remote thumbnail source whitelist: newsatcl-pctr.c.yimg.jp
  １０月から始まる新型コロナワクチン定期接種　誰が対象？　費用はいくら？（倉原優） - エキスパート - Yahoo!ニュース
  １０月１日から、新型コロナワクチンの定期接種が始まります。どのようなワクチンが使用され、接種費用はどのくらいかかるのでしょうか。現時点で分かっていることをお伝えします。接種対象者は？今年の秋冬に、自治

Public

Embed Notice

HTML Code

Corresponding Notice